首页> 外文会议>Society for Biomaterials annual meeting and exposition >Transplant tolerance to minor antigen mismatched bone marrow grafts using PLG particles
【24h】

Transplant tolerance to minor antigen mismatched bone marrow grafts using PLG particles

机译:使用PLG颗粒对微小抗原错配的骨髓移植的移植耐受性

获取原文

摘要

The CD4 male-specific Dby epitope induces tolerance to minor HY antigen mismatched bone marrow grafts, both when coupled to the surface of PLG particles and encapsulated within PLG particles. The percentage of engrafting donor bone marrow cells in tolerized recipients exceeded 50% in several animals, and a single particle dose on Day +1 was sufficient for tolerance. Conversely, the CD8 Uty epitope did not induce tolerance, indicating that CD4 T cells are the primary mediator of graft rejection in this model. Future studies will address transplant tolerance in a fully MHC mismatched allogeneic model, where the donor antigens are numerous and unidentified. Using PLG particles as a platform for inducing tolerance in minor HY antigen mismatched bone marrow transplantation is a key step in developing a translatable, donor-specific tolerance strategy for modern transplantation procedures.
机译:当偶联至PLG颗粒的表面并包封在PLG颗粒中时,CD4雄性特异性Dby表位诱导对较小的HY抗原错配的骨髓移植物的耐受性。在几只动物中,在耐受的受体中移植供体骨髓细胞的百分比超过50%,并且在第+1天单粒剂量足以耐受。相反,CD8 Uty表位不诱导耐受,表明在该模型中CD4 T细胞是移植排斥的主要介质。未来的研究将在完全MHC错配的同种异体模型中解决移植耐受性,其中供体抗原众多且未被鉴定。使用PLG颗粒作为诱导轻微HY抗原错配的骨髓移植耐受的平台,是为现代移植程序开发可翻译的,供体特异性耐受策略的关键步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号